An autoimmune hope passes its first safety test in people

Zealand Pharma's experimental treatment ZP9830 has cleared its first multiple-dose test in people. The drug blocks a channel called Kv1.3, a switch found on the immune cells that drive cell-mediated autoimmune diseases — conditions in which the body's own defences attack it. In the multiple-ascending-dose part of its Phase 1 trial, repeated doses were well tolerated: no serious or severe side effects and no dose-limiting safety findings. Phase 1 results are the earliest rung of human testing — they show a drug can be given safely, not yet that it works — but the company describes ZP9830 as a possible 'pipeline in a product', one mechanism that could, in time, be tested across a broad range of autoimmune conditions. The next step is proving benefit in patients.

SDG 3 · Good health and well-being — Mechanism: tech innovation